• PARP inhibitors block the action of an enzyme that helps repair DNA. Without the ability to repair their DNA, tumor cells can die or more easily be killed by chemo.
Monday, June 1, 2009
New drug being tested for triple-negative breast cancer
News from the 2009 annual meeting of the American Society of Clinical Oncology: PARP inhibitors continue to be a promising line of attack for triple negative. In a study presented at the conference on a new drug, BS-201, which includes a PARP inhibitor:
• of 116 women with advanced triple-negative breast cancer, those who received the drug in addition to standard chemotherapy lived a median of 9.2 months, compared with 5.7 months for those who received only the chemotherapy.